目的：探讨18F-FDG PET/CT显像在诊断腹膜后纤维化中的价值。资料和方法：回顾性分析2013年1月—2016年10月18例通过影像学检查配合临床随访1年以上（10例）、病理（8例）证实为腹膜后纤维化患者的资料，其中7例临床实验室指标（C反应蛋白、血沉升高等）提示为活动期，11例处于非活动期。结果：18例患者在CT上均表现为腹膜后不规则软组织肿块，多与周围组织界限不清，肿块可包绕腹主动脉、髂动脉、输尿管等。7例活动期患者中的5例为初诊患者，PET显像表现为肿块18F-FDG摄取异常增高，另2例已分别接受激素治疗2月及2.5月，PET提示肿块18F-FDG代谢未见明显增高。在11例非活动期初诊患者中，腹膜后肿块表现为18F-FDG代谢高低不等。结论：18F-FDG PET/CT不仅可通过CT清晰显示腹膜后纤维化的病灶范围，而且PET显像的18F-FDG代谢程度有助于判断病变是否处于活动期以及评价病变对激素治疗的疗效反应。
Abstract
Objective: To investigate the value of 18F-FDG PET/CT imaging in the diagnosis of retroperitoneal fibrosis. Materials and Methods: A retrospective analysis of 18 cases with retroperitoneal fibrosis from January 2013 to October 2016 confirmed by imaging examination with clinical follow-up of more than one year(10 cases) and pathology(8 cases) was performed, including 7 cases in the active phase and 11 cases in the inactive phase with evidence from serum laboratory findings(obviously hige C reactive protein and erythrocyte sedimentation rate). Results: The CT images of 18 patients showed irregular soft tissue masses in retroperitoneum, with unclear boundaries often involving the abdominal aorta, iliac artery, ureter and so on. Five of the 7 patients in the active phase were initially diagnosed, with increased FDG uptake in the masses on PET images. The rest 2 patients had already begun their steroid treatment since 2 and 2.5 months ago respectively, with no significant increase in FDG metabolism on PET images. In the 11 patients with inactive retroperitoneal masses which were initially diagnosed, the FDG metabolism varied. Conclusion: 18F-FDG PET/CT can clearly show the range of retroperitoneal fibrosis by CT, and FDG metabolism on PET is helpful to determine whether the lesion is in the active phase and to evaluate the effect of steroid treatment.
关键词
腹膜后纤维化 /
氟脱氧葡萄糖F18 /
正电子发射断层显像术
Key words
Retroperitoneal fibrosis /
Fluorodeoxyglucose F18 /
Positron-emission tomography
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1]Greco P, Vaglio A, Manenti L, et al. Idiopathic retroperitoneal fibrosis[J]. G Ital Nefrol, 2004, 21(2): 132-138.
[2]李清勇. 64排螺旋CT在诊断腹膜后纤维化中的应用价值[J]. 医药论坛杂志，2013，34（4）：134-135.
[3]Vaglio A, Salvarani C, Buzio C. Retroperitoneal fibrosis[J]. Lancet, 2006, 367(9506): 241-251.
[4]余成秀，罗雄燕，邹倩，等. LgG4与自身免疫病[J]. 中华风湿学杂志，2012，16（12）：838-840.
[5]陈永刚，戴岷. 隐匿起病的腹膜后纤维化3例临床分析[J]. 中国医师杂志，2015（s1）：158-159.
[6]Fofi C, Prosperi D, Pettorini L, et al. Diagnosis and follow-up of idiopathic retroperitoneal fibrosis: role of 18F-FDG-PET/CT and biochemical parameters in patients with renal involvement[J]. Intern Emerg Med, 2016, 11(6): 809-816.
[7]Washino S, Hirai M, Matsuzaki A, et al. 18F-Fluorodeoxyglucose positron emission tomography for diagnosis and monitoring of idiopathic retroperitoneal fibrosis associated with mediastinal fibrosis[J]. Ann Nucl Med, 2010, 24(3): 225-229.
[8]Nakajo M, Jinnouchi S, Tanabe H, et al. 18F-fluorodeoxyglucose positron emission tomography features of idiopathic retroperitoneal fibrosis[J]. J Comput Assist Tomogr, 2007, 31(4): 539-543.
[9]Moroni G, Castellani M, Balzani A, et al. The value of 18F-FDG PET/CT in the assessment of active idiopathic retroperitoneal fibrosis[J]. Eur J Nucl Med Mol Imaging, 2012, 39(10): 1635-1642.
[10]Jansen I, Hendriksz TR, Han SH, et al. 18F-fluorodeoxyglucose position emission tomography(FDG-PET) for monitoring disease activity and treatment response in idiopathic retroperitoneal fibrosis[J]. Eur J Intern Med, 2010, 21(3): 216-221.
[11]张警丰，赵金霞，刘湘源. 特发性腹膜后纤维化诊治研究进展[J]. 中华风湿病学杂志，2015，19（8）：567-569.
[12]Treglia G, Mattoli MV, Bertagna F, et al. Emerging role of Fluorine-18-fluorodeoxyglucose positron emission tomography in patients with retroperitoneal fibrosis: a systematic review[J]. Rheumatol Int, 2013, 33(3): 549-555.
[13]Bertagna F, Treglia G, Leccisotti L, et al. [18F]FDG-PET/CT in patients affected by retroperitoneal fibrosis: a bicentric experience[J]. Jpn J Radiol, 2012, 30(5): 415-421.
